Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
PaperCitations, authors & open-access status
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 686 citations, 2017 year and green oa status.
686
Citations
2017
Year
green
OA Status